35Pharma 1a.png
35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity
November 26, 2024 08:00 ET | 35Pharma Inc.
35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
November 20, 2024 07:55 ET | ZyVersa Therapeutics
Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.
800 px horizontal logo.png
CORRECTION - Elevai Labs Inc.
November 14, 2024 14:35 ET | Elevai Labs Inc.
/CORRECTION/ Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update
800 px horizontal logo.png
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
November 14, 2024 09:08 ET | Elevai Labs Inc.
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
November 14, 2024 08:10 ET | ZyVersa Therapeutics
ZyVersa announces progress toward achieving key near-term development milestones and Q3-2024 financials.
Zealand Logo (1).png
Zealand Pharma to participate in the Jefferies London Healthcare Conference
November 13, 2024 12:00 ET | Zealand Pharma
Press Release – No. 11 / 2024 Zealand Pharma to participate in the Jefferies London Healthcare Conference Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078),...
Fractyl-Logo.png
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 12, 2024 16:05 ET | Fractyl Health, Inc.
REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025
kailera logo.png
Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer
November 12, 2024 08:00 ET | Kailera Therapeutics, Inc.
Today, Kailera Therapeutics announced the appointment of Scott Akamine as Chief Legal Officer.
Rani-Logo.jpg
Rani Therapeutics to Participate in Upcoming Investor Conferences
November 07, 2024 16:05 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
November 05, 2024 07:00 ET | ZyVersa Therapeutics
Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.